$26.00 Million in Sales Expected for Nektar Therapeutics (NASDAQ:NKTR) This Quarter

Share on StockTwits

Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will post $26.00 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $23.60 million and the highest is $28.50 million. Nektar Therapeutics reported sales of $39.83 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 34.7%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that Nektar Therapeutics will report full year sales of $106.99 million for the current financial year, with estimates ranging from $104.40 million to $110.00 million. For the next fiscal year, analysts forecast that the company will post sales of $150.30 million, with estimates ranging from $100.89 million to $205.71 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.17. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company had revenue of $29.22 million during the quarter, compared to the consensus estimate of $26.42 million. During the same period in the prior year, the company earned ($0.56) earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year.

Several equities research analysts have issued reports on NKTR shares. Evercore ISI restated a “hold” rating and issued a $37.00 price target on shares of Nektar Therapeutics in a report on Sunday, August 11th. Cfra set a $35.00 price target on Nektar Therapeutics and gave the stock a “hold” rating in a report on Friday, August 9th. Mizuho restated a “hold” rating and issued a $21.00 price target on shares of Nektar Therapeutics in a report on Thursday, November 7th. BidaskClub downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright increased their price target on Nektar Therapeutics from $24.00 to $32.00 and gave the stock a “neutral” rating in a report on Monday, November 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $30.00.

Shares of Nektar Therapeutics stock traded down $0.25 during trading hours on Thursday, hitting $20.29. The company’s stock had a trading volume of 1,183,979 shares, compared to its average volume of 3,234,537. Nektar Therapeutics has a 12 month low of $15.64 and a 12 month high of $47.11. The stock has a 50 day moving average of $18.53 and a 200 day moving average of $24.92. The company has a market capitalization of $3.61 billion, a PE ratio of 5.37 and a beta of 2.62. The company has a debt-to-equity ratio of 0.26, a current ratio of 12.60 and a quick ratio of 12.49.

In related news, SVP Stephen K. Doberstein purchased 15,000 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was purchased at an average cost of $17.28 per share, for a total transaction of $259,200.00. Following the completion of the purchase, the senior vice president now directly owns 107,668 shares in the company, valued at $1,860,503.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $17.99, for a total value of $71,960.00. Following the completion of the transaction, the director now owns 276,973 shares of the company’s stock, valued at $4,982,744.27. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 175,178 shares of company stock valued at $3,738,898. 4.02% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. grew its stake in Nektar Therapeutics by 1,057.7% in the second quarter. Invesco Ltd. now owns 23,343,019 shares of the biopharmaceutical company’s stock valued at $830,544,000 after purchasing an additional 21,326,731 shares in the last quarter. Vanguard Group Inc. grew its stake in Nektar Therapeutics by 2.0% in the second quarter. Vanguard Group Inc. now owns 18,512,772 shares of the biopharmaceutical company’s stock valued at $658,684,000 after purchasing an additional 356,193 shares in the last quarter. BlackRock Inc. grew its stake in Nektar Therapeutics by 6.0% in the second quarter. BlackRock Inc. now owns 13,264,987 shares of the biopharmaceutical company’s stock valued at $471,969,000 after purchasing an additional 749,644 shares in the last quarter. State Street Corp grew its stake in Nektar Therapeutics by 3.9% in the third quarter. State Street Corp now owns 7,419,493 shares of the biopharmaceutical company’s stock valued at $135,146,000 after purchasing an additional 276,983 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in Nektar Therapeutics by 39.9% in the second quarter. First Trust Advisors LP now owns 3,005,999 shares of the biopharmaceutical company’s stock valued at $106,953,000 after purchasing an additional 856,819 shares in the last quarter. Hedge funds and other institutional investors own 99.77% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: FAANG Stocks

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.